Global platform brings together the top 100 business leaders who are combining profit and purpose to help achieve the UN Sustainable Development Goals
Chr. Hansen reaches 7% organic growth in 2018/19
Despite more challenging growth conditions Chr. Hansen delivers a strong EBIT margin and a healthy cash flow, while also making significant progress on key strategic priorities
Chr. Hansen’s good bacteria to be produced on solar power
A new 10-year agreement enables Chr. Hansen Denmark to switch 100% to green power from two brand new solar parks. The agreement underlines Chr. Hansen’s commitment to a sustainable future and will create more green energy capacity to the benefit of all of Denmark.
Chr. Hansens gode bakterier skal fremstilles på solenergi
En ny tiårig aftale med Better Energy betyder, at Chr. Hansen kan overgå 100% til grøn strøm fra to helt nye solcelleparker. Aftalen understreger Chr. Hansens dedikation til en bæredygtig fremtid og skaber mere grøn energi til hele Danmark.
Chr. Hansen and Lonza’s newly branded joint venture, BacThera, receives anti-trust approvals to start contract manufacturing of live biotherapeutic products
Chr. Hansen Holding A/S, a leading global bioscience company, and Lonza AG, a leading pharma contract manufacturing company, announce today that they have received the relevant approvals from anti-trust regulators needed to establish the 50/50 joint venture in the emerging market for live biotherapeutic products, which was originally announced in Company Announcement No. 04 on April 2, 2019.